Cargando…

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects

PURPOSE: Poly(ADP-ribose) polymerase 1 (PARP1) is necessary for single-strand break (SSB) repair by sensing DNA breaks and facilitating DNA repair through poly ADP-ribosylation of several DNA-binding and repair proteins. Inhibition of PARP1 results in collapsed DNA replication fork and double-strand...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hong-Yuan, Tang, Hai-Long, Zheng, Yan-Hua, Feng, Juan, Dong, Bao-Xia, Chen, Xie-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005285/
https://www.ncbi.nlm.nih.gov/pubmed/35422863
http://dx.doi.org/10.1155/2022/2800488
_version_ 1784686425220841472
author Shen, Hong-Yuan
Tang, Hai-Long
Zheng, Yan-Hua
Feng, Juan
Dong, Bao-Xia
Chen, Xie-Qun
author_facet Shen, Hong-Yuan
Tang, Hai-Long
Zheng, Yan-Hua
Feng, Juan
Dong, Bao-Xia
Chen, Xie-Qun
author_sort Shen, Hong-Yuan
collection PubMed
description PURPOSE: Poly(ADP-ribose) polymerase 1 (PARP1) is necessary for single-strand break (SSB) repair by sensing DNA breaks and facilitating DNA repair through poly ADP-ribosylation of several DNA-binding and repair proteins. Inhibition of PARP1 results in collapsed DNA replication fork and double-strand breaks (DSBs). Accumulation of DSBs goes beyond the capacity of DNA repair response, ultimately resulting in cell death. This work is aimed at assessing the synergistic effects of the DNA-damaging agent temozolomide (TMZ) and the PARP inhibitor niraparib (Nira) in human multiple myeloma (MM) cells. MATERIALS AND METHODS: MM RPMI8226 and NCI-H929 cells were administered TMZ and/or Nira for 48 hours. CCK-8 was utilized for cell viability assessment. Cell proliferation and apoptosis were detected flow-cytometrically. Immunofluorescence was performed for detecting γH2A.X expression. Soft-agar colony formation assay was applied to evaluate the antiproliferative effect. The amounts of related proteins were obtained by immunoblot. The combination index was calculated with the CompuSyn software. A human plasmacytoma xenograft model was established to assess the anti-MM effects in vivo. The anti-MM activities of TMZ and/or Nira were evaluated by H&E staining, IHC, and the TUNEL assay. RESULTS: The results demonstrated that cotreatment with TMZ and Nira promoted DNA damage, cell cycle arrest, and apoptotic death in cultured cells but also reduced MM xenograft growth in nude mice, yielding highly synergistic effects. Immunoblot revealed that TMZ and Nira cotreatment markedly increased the expression of p-ATM, p-CHK2, RAD51, and γH2A.X, indicating the suppression of DNA damage response (DDR) and elevated DSB accumulation. CONCLUSION: Inhibition of PARP1 sensitizes genotoxic agents and represents an important therapeutic approach for MM. These findings provide preliminary evidence for combining PARP1 inhibitors with TMZ for MM treatment.
format Online
Article
Text
id pubmed-9005285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90052852022-04-13 The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects Shen, Hong-Yuan Tang, Hai-Long Zheng, Yan-Hua Feng, Juan Dong, Bao-Xia Chen, Xie-Qun J Oncol Research Article PURPOSE: Poly(ADP-ribose) polymerase 1 (PARP1) is necessary for single-strand break (SSB) repair by sensing DNA breaks and facilitating DNA repair through poly ADP-ribosylation of several DNA-binding and repair proteins. Inhibition of PARP1 results in collapsed DNA replication fork and double-strand breaks (DSBs). Accumulation of DSBs goes beyond the capacity of DNA repair response, ultimately resulting in cell death. This work is aimed at assessing the synergistic effects of the DNA-damaging agent temozolomide (TMZ) and the PARP inhibitor niraparib (Nira) in human multiple myeloma (MM) cells. MATERIALS AND METHODS: MM RPMI8226 and NCI-H929 cells were administered TMZ and/or Nira for 48 hours. CCK-8 was utilized for cell viability assessment. Cell proliferation and apoptosis were detected flow-cytometrically. Immunofluorescence was performed for detecting γH2A.X expression. Soft-agar colony formation assay was applied to evaluate the antiproliferative effect. The amounts of related proteins were obtained by immunoblot. The combination index was calculated with the CompuSyn software. A human plasmacytoma xenograft model was established to assess the anti-MM effects in vivo. The anti-MM activities of TMZ and/or Nira were evaluated by H&E staining, IHC, and the TUNEL assay. RESULTS: The results demonstrated that cotreatment with TMZ and Nira promoted DNA damage, cell cycle arrest, and apoptotic death in cultured cells but also reduced MM xenograft growth in nude mice, yielding highly synergistic effects. Immunoblot revealed that TMZ and Nira cotreatment markedly increased the expression of p-ATM, p-CHK2, RAD51, and γH2A.X, indicating the suppression of DNA damage response (DDR) and elevated DSB accumulation. CONCLUSION: Inhibition of PARP1 sensitizes genotoxic agents and represents an important therapeutic approach for MM. These findings provide preliminary evidence for combining PARP1 inhibitors with TMZ for MM treatment. Hindawi 2022-04-05 /pmc/articles/PMC9005285/ /pubmed/35422863 http://dx.doi.org/10.1155/2022/2800488 Text en Copyright © 2022 Hong-Yuan Shen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shen, Hong-Yuan
Tang, Hai-Long
Zheng, Yan-Hua
Feng, Juan
Dong, Bao-Xia
Chen, Xie-Qun
The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title_full The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title_fullStr The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title_full_unstemmed The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title_short The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
title_sort parp1 inhibitor niraparib represses dna damage repair and synergizes with temozolomide for antimyeloma effects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005285/
https://www.ncbi.nlm.nih.gov/pubmed/35422863
http://dx.doi.org/10.1155/2022/2800488
work_keys_str_mv AT shenhongyuan theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT tanghailong theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT zhengyanhua theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT fengjuan theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT dongbaoxia theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT chenxiequn theparp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT shenhongyuan parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT tanghailong parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT zhengyanhua parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT fengjuan parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT dongbaoxia parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects
AT chenxiequn parp1inhibitorniraparibrepressesdnadamagerepairandsynergizeswithtemozolomideforantimyelomaeffects